Progyny, Inc. PGNY
At closeNov 3, 2026, 4:06 PM EST
After hours · Nov 3, 4:06 PM ET
- YTD
- +13.16%
- 1 year
- +57.68%
- Market cap
- 2.23B
- Revenue (ttm)
- 1.31B
- Profit margin
- 6.00%
- EPS (ttm)
- 0.92
- Shares out
- 76.73M
- P/E ratio
- 31.59
- Forward P/E
- 12.56
- YTD return
- +13.16%
- 1-year return
- +57.68%
- Volume
- 970.84K
- Avg volume
- 1.10M
- Open
- 29.29
- Previous close
- 29.41
- Day's range
- 28.95 – 29.71
- 52-week range
- 16.10 – 33.07
- Beta
- 0.95
- Price target
- 34.42 (+18.4%)
- Earnings date
- Nov 4, 2026
2Y +13.84 (+91.35%)
Key statistics
- Enterprise value
- 2.05B
- PEG ratio
- 0.00
- Price / sales
- 1.70
- Price / book
- 4.92
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 5.30%
- Free cash flow
- 196.47M
- Total cash
- 236.92M
- Total debt
- 26.97M
- Return on equity
- 16.24%
- Short % of float
- 8.93%
- 50-day average
- 26.95
- 200-day average
- 24.39
Analyst view
- Target (low)
- 30.00
- Target (mean)
- 34.42
- Target (high)
- 40.00
- Strong buy1
- Buy9
- Hold2
- Sell0
- Strong sell0
Next earnings
Nov 4, 2026
Expected Nov 4, 2026. Consensus EPS estimate 0.50894.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 4, 2026 | Sep 30, 2026 | 0.313 | — | — | — |
| Aug 6, 2026 | Jun 30, 2026 | 0.3348 | 0.36 | +0.03 | +7.53% |
| May 7, 2026 | Mar 31, 2026 | 0.256 | 0.30 | +0.04 | +17.19% |
| Feb 26, 2026 | Dec 31, 2025 | 0.147 | 0.15 | 0.00 | +2.04% |
| Nov 6, 2025 | Sep 30, 2025 | 0.39 | 0.16 | -0.23 | -58.97% |
| Aug 7, 2025 | Jun 30, 2025 | 0.17 | 0.20 | +0.03 | +17.65% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 30, 2026 | Wells Fargo | init | — | Overweight |
| Sep 8, 2026 | Citizens | main | Market Outperform | Market Outperform |
| Aug 21, 2026 | JP Morgan | main | Neutral | Neutral |
| Aug 20, 2026 | Wells Fargo | init | — | Overweight |
| Aug 13, 2026 | Truist Securities | main | Buy | Buy |
| Aug 12, 2026 | Barclays | main | Equal-Weight | Equal-Weight |
About Progyny, Inc.
Progyny, Inc., a benefits management company, provides fertility, family building, and women's health benefits solutions in the United States. It offers fertility benefits solutions, such as differentiated benefits plan design that includes smart cycle treatment bundle; personalized concierge-style member support services; and a selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides access to the medications needed during their treatment and offers care management services, as well as pregnancy and postpartum, menopause and midlife, benefit and leave navigation, and parent and child wellbeing solutions. In addition, it provides assistance service program where various services can be offered through a reimbursement program, including adoption, surrogacy, doula, and travel reimbursement when travel is required to receive medical services. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.
- Sector
- Healthcare
- Industry
- Healthcare Plans
- Country
- United States
- Website
- progyny.com
News
New Progyny Study Examines Persistent Racial and Ethnic Differences in Fertility Treatment Initiation Despite Access to Benefits 
New Progyny Study Finds Significant Improvement in Menopause Symptoms Through Connected Care Model 
Progyny, Inc. Announces Details for Its Third Quarter 2026 Results Report 
Progyny (NASDAQ:PGNY) COO Sells $52,612.00 in Stock 
Progyny to Present New Menopause Research at The Menopause Society 2026 Annual Meeting 
Progyny (PGNY) Soars 6.3%: Is Further Upside Left in the Stock? 
PGNY or CRL: Which Is the Better Value Stock Right Now? 
Progyny, Inc. Selling Season Pacing to Record Level, Revealing Critical Insights on Latest Market Dynamics 
PGNY vs. CRL: Which Stock Is the Better Value Option? 
Progyny: Best-In-Class And Likely To Exceed Analyst Estimates In 2027
Your note
Sign in to keep a note on PGNY — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ANEVSKI PETER | Chief Executive Officer | Stock Award(Grant) | Mar 1, 2026 | 816,834 |
| CLAPP GEOFFREY | Officer | Conversion of Exercise of derivative security | Jun 1, 2026 | 60,647 |
| CUMMINGS MELISSA B | Chief Operating Officer | Sale | Jul 13, 2026 | 69,934 |
| DEAN LLOYD H | Director | Stock Award(Grant) | May 20, 2026 | 26,519 |
| HOLSTEIN ROGER C | Director | Stock Award(Grant) | May 20, 2026 | 28,729 |
| LIVINGSTON MARK S | Chief Financial Officer | Sale | Jun 3, 2026 | 74,688 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 15.12% | 11,599,921 | 337.09M | Jun 29, 2026 |
| FMR, LLC | 9.13% | 7,004,280 | 203.54M | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 6.54% | 5,019,465 | 145.87M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 4.18% | 3,210,723 | 93.30M | Jun 29, 2026 |
| State Street Corporation | 3.94% | 3,022,859 | 87.84M | Jun 29, 2026 |
| Ameriprise Financial, Inc. | 3.60% | 2,763,514 | 80.31M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Trust-iShares Core S&P Small-Cap ETF | 5.95% | 4,566,776 | 132.71M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.92% | 2,242,829 | 65.18M | Jun 29, 2026 |
| Touchstone Strategic TRT-Touchstone Strategic TRT-Touchstone Small Com | 2.53% | 1,940,666 | 56.40M | Jun 29, 2026 |
| American Century ETF Trust-Avantis U.S. Small Cap Value ETF | 2.51% | 1,928,807 | 56.05M | Sep 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.48% | 1,902,275 | 55.28M | Sep 29, 2026 |
| Fidelity Securities Fund-Fidelity Small Cap Growth Fund | 2.18% | 1,676,019 | 48.71M | Jul 30, 2026 |